Menu
Search
|

Menu

Close
X

G1 Therapeutics Inc GTHX.OQ (NASDAQ Stock Exchange Global Select Market)

44.67 USD
+1.52 (+3.52%)
As of 1:30 AM IST
chart
Previous Close 43.15
Open 42.74
Volume 171,549
3m Avg Volume 114,804
Today’s High 45.06
Today’s Low 41.29
52 Week High 52.76
52 Week Low 12.04
Shares Outstanding (mil) 28.29
Market Capitalization (mil) 731.75
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.695
FY17
-2.399
FY16
-1.266
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
5.92
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
--
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

Seth Rudnick
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mark Velleca
President, Chief Executive Officer, Director, Since 2014
Salary: $405,000.00
Bonus: $133,650.00
Barclay Phillips
Chief Financial Officer and Senior Vice President - Corporate Development, Since 2017
Salary: --
Bonus: --
Jay Strum
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Jennifer Moses
Vice President - Finance and Administration, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

79 T.W. Alexander Drive
4501 Research Commons, Suite 100
RESEARCH TRIANGLE PARK   NC   27709

Phone: +1919.2139835

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

SPONSORED STORIES